• New drugs that inhibit HBV replication are needed to enhance the treatment of chronic hepatitis B resulting in a higher number of durable responses and functional cures.
  • Capsid-assembly modulators (CAM) are a novel class of HBV antivirals and they have been suggested to be effective anti-HBV agents in both preclinical and clinical studies.
  • CAMs have multiple mechanisms of action.
    • Inhibition of virus proliferation
      • Inhibit creation of additional hepatitis viruses
      • Prevent cccDNA accumulation
    • Eradication cytolytic infected cells
      • Decreasing level of HBsAg and HBeAg
    • Eradication non-cytolytic infected cells
      • Restoration of antiviral cytokine activity
      • Promoting APOBEC activity
  • Potent antiviral activity via multiple MOAs may be important for optimal patient responses.

Authors: J. KIM, M. LEE, H. SIM, R. KIM, B. PAK, P. PRASIT, N. JEONG

See poster

Back to Resources